Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010 Jun; 117(6):1102-1112.e1.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.